 CORAL GABLES, Fla. , Aug. 5, 2022 PRNewswire -- Relmada Therapeutics, Inc. Nasdaq: RLMD, a late-stage biotechnology company addressing diseases of the central nervous system CNS, today announced that it will report its financial results for the second quarter and six months ended June 30, 2022, after the market close on Thursday, August 11, 2022. 